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Accepted 21 September 2011; Published online 24 January 2012AbstractObjective: Many recent studies investigated the prognostic value of new biomarkers in breast cancer using data from cancer registries.
Some of these studies were conducted using only patients for whom biomarker status was available (or tested). Using human epidermal
growth factor receptor 2 (HER2) as an example, we determined whether testing for a recently introduced biomarker was associated with
the outcome of women with breast cancer.
Study Design and Setting: We included 910 women with newly diagnosed breast cancer in a tertiary academic hospital in Kuala
Lumpur, Malaysia, between 2005 and 2007. Individual 2-year absolute mortality risk was estimated using Cox regression analysis. Logistic
regression was used to assess the association between the absolute mortality risk and assessment of HER2 status.
Results: There was a significant inverted U-shaped association between predicted mortality risk and HER2 status determination.
Compared with patients with the lowest predicted mortality risk (quintile 1), patients with highest predicted mortality risk (last quintile)
were significantly less likely to be tested for HER2 status, whereas those with intermediate predicted mortality risk (quintile 3) were more
likely to be tested.
Conclusion: Breast cancer prognostication using only patients with available biomarker status may lead to invalid results.
 2012 Elsevier Inc.
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Accurate prediction of survival in patients with breast
cancer is important because it drives treatment decisions
and patient counseling. In clinical (breast) cancer research,
there is substantial interest in new biomarkers, which may
serve as prognostic or predictive indicators [1].
A number of recent prognostic studies investigating
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Open access under the Elsevier OA license.of breast cancer patients [2e6]. These registries usually
span over periods during which implementation of the
biomarker under study was a gradual process. In the earlier
years of the registry, such biomarkers may have been
sporadically tested for, often in the context of clinical trials.
In the later years, as the potential benefit of testing for the
biomarkers became clearer, the tests were routinely
applied. Therefore, using such registry data for prognostic
studies focusing on newly implemented biomarkers may
pose a problem. There are studies that provide data on
biomarkers as prognostic factors using complete case
analysis; based on patient groups who have available
information on biomarker status. This may yield valid esti-
mates if the selection process for biomarker determination
at diagnosis is a random process. It will, however, yield
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 Selection of patients for determination of recently
implemented biomarkers in regular clinical care
for breast cancer is not a random process but rather
based on patients’ prognoses.
 In a real clinical setting, we have demonstrated the
pitfall of performing naive complete case analysis
to study prognostic value of newly implemented
biomarkers in breast cancer.
 Restriction of prognostication to women with
available biomarkers may lead to invalid estima-
tions, that is, underestimation of risk of mortality
if only patients with favorable characteristics were
tested for biomarkers.
 Comparing characteristics or survival of patients
who had information against those with missing in-
formation may provide an idea on the extent of
selection bias.biased prognostic estimates if such selection is nonrandom
and associated with the outcome of the patient.
Because the implementation of a new biomarker
measurement in clinical practice is a gradual process, we
speculated that a clinician’s decision to determine new
biomarkers depends on the perceived patient’s prognosis
at the time of diagnosis. Our research question was whether
in clinical settings, testing for the recently implemented
biomarker HER2 in newly diagnosed breast cancer patients
was associated with their perceived mortality risk.2. Methods
Data from the University Malaya Medical Centre
(UMMC) Breast Cancer Registry were used in this study.
UMMC is a tertiary academic hospital in Kuala Lumpur,
Malaysia, which caters to a predominantly middle class
urban population. Because testing for HER2 status in
UMMC started in mid-2000s, 910 consecutive patients
who were newly diagnosed with invasive breast cancer
between 2005 and 2007 were included in this analysis.
Requests for HER2 testing in these women had either been
done by the breast surgeon or the oncologist. During the
study era, HER2 testing was predominantly performed on
surgically resected specimens.
In this registry, patient’s age, TNM stage, tumor size,
lymph node status, tumor grade, estrogen and progesterone
receptor status were available for most patients. The assump-
tion in this study was that clinicians estimate the survival for
womenwith breast cancer around the time of diagnosis using
the above-mentioned patient characteristics. The registrydata were used to mimic that process by estimating the abso-
lute 2-year mortality risk for individual patients based on
these characteristics.3. Data analysis
To assess whether clinicians based their decision to
determine HER2 status on perceived patient outcome, we
compared known prognostic factors, available at time of
diagnosis, between those who were tested and untested
for HER status, using logistic regression.
Survival analysis was performed using Cox regression
with time to death as dependent variable. Clinical indicators
of prognosis that were entered as predictor variables into the
Cox model were age (continuous), tumor size (continuous),
lymph node involvement (yes, no, unknown), distant metas-
tasis (yes, no), tumor grade (low, medium, high, unknown),
estrogen receptor status (yes, no, unknown), and progester-
one receptor status (yes, no, unknown). Ethnicity, which is
a prognostic predictor of survival, was also included in the
model [7]. Observation times of women were calculated as
time between diagnosis and death (all causes), last contact
or November 2010. From the above model, absolute individ-
ual 2-yearmortality riskswere estimated for all women [8,9].
These estimates represent the predicted risks according
to the model of survival for each patient with her given
follow-up time and predictor values. They are defined as:
S(t)5 S0(t)
exp(LP), where the linear predictor (LP) is
b1 * X1þ b2 * X2þ/, with the X denoting the predictor
values and b the regression coefficients. The baseline
survival function S0(t) is the time-dependent cumulative
probability of survival for a woman with none of the
predictors present, that is, the LP being zero and thus
S0(t)5 (S[t]). The baseline survival function (S0[t]) can
be calculated by remolding the above formula as follows:
S0(t)5 S(t)
1/exp(LP). This calculation allowed us to obtain
the cumulative 24-month survival from those women who
actually had 24 months of follow-up (S0[24 months]). The
next step was to calculate the 24-month survival for all
patients using the baseline survival function of women with
actual 24 months follow-up S0(24 months) and the LP
that represents the individual part of the risk. Hence,
S(24 months)5 S0(24 months)
exp(LP)5 0.9526 exp(LP). The
24-month time span was arbitrarily chosen, not only
primarily on clinical grounds but also because at the time
of follow-up, the number of patients at risk was still suffi-
ciently large. Subsequently, univariable logistic regression
was used to estimate the association between the individual
2-year mortality risk (quintile) as independent variable and
assessment of biomarker status (yes/no) as the dependent
variable. To test for trends, we entered the quintiles as
a continuous variable (assess linear trend) and squared term
(assess quadratic trend) into the logistic regression model.
Two-tailed P-values below 0.05 and odds ratios (ORs)
with 95% confidence interval (CI) that did not include
1.00 were considered as statistically significant. All
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dows (SPSS Inc., Chicago, IL, USA).4. Results
Of 910 women in this study, 855 (94%) were tested for
HER2 status, whereas 55 were not. Patients who were
tested were younger, less often of Malay ethnicity, had
smaller tumors, and were less likely to have metastatic
breast cancer (Table 1).
Fig. 1 shows the distribution of predicted absolute 2-year
mortality risks at diagnosis for 910 women with breast
cancer between 2005 and 2007. Most women had low
predicted mortality risk with a median of 4% and a range
spanning from close to 0% to almost 100%.Table 1. Differences in patient characteristics between women
diagnosed with breast cancer who were tested for HER2 status
and those who were not tested
Characteristics
HER2 status determined
OR of HER2 testing*
(95% CI)
Yes
N[ 855
n (%)
No
N[ 55
n (%)
Age category (y)
!35 42 (5.5) 3 (4.9) 0.73 (0.22e2.46)
35e64 674 (78.8) 35 (63.6) 1.00
65 139 (16.3) 17 (30.9) 0.43 (0.23e0.78)
Ethnicity
Chinese 600 (70.2) 28 (50.9) 1.00
Malay 152 (17.8) 19 (34.5) 0.37 (0.20e0.69)
Indian 103 (12.0) 8 (14.5) 0.60 (0.27e1.36)
Tumor size (mean)y 3.80 6.20 0.89 (0.84e0.93)
Lymph node
involvement
Yes 378 (44.4) 27 (50.9) 0.77 (0.44e1.34)
No 474 (55.6) 26 (49.1) 1.00
Unknown 3 2
Distant metastasis
Yes 47 (5.5) 18 (32.7) 0.12 (0.06e0.23)
No 808 (94.5) 37 (67.3) 1.00
Grade
Low 51 (6.0) 5 (9.1) 0.37 (0.12e1.10)
Moderate 332 (38.8) 13 (23.6) 0.92 (0.41e2.09)
High 305 (35.7) 11 (20.0) 1.00
Unknown 167 (19.5) 26 (47.3) 0.23 (0.11e0.48)
Estrogen receptor
status
Negative 372 (43.5) 11 (28.2) 1.00
Positive 483 (56.5) 28 (71.8) 0.51 (0.25e1.04)
Unknown 0 16 d
Progesterone
receptor status
Negative 434 (50.8) 11 (36.7) 1.00
Positive 421 (49.2) 19 (63.3) 0.56 (0.26e1.19)
Unknown 0 25 d
Abbreviations: HER2, human epidermal growth factor receptor 2;
OR, odds ratio; CI, confidence interval.
* Derived using univariable logistic regression model with
determination of HER2 status (yes/no) as the dependent variable
and patient characteristic as independent variable.
y Available in 888 patients.
Fig. 1. Distribution of predicted 2-year mortality risk in 888Malaysian
women with breast cancer.Table 2 shows the association between the predicted
mortality risk and testing of HER2 status among the breast
cancer patients. Women with the highest risk of mortality
(quintile 5) were significantly less likely to have their
HER2 status tested compared with those with the lowest
mortality risk (quintile 1 reference); OR: 0.36 (95% CI:
0.17, 0.77), whereas patients with intermediate mortality
risk (quintile 3) were more likely to be tested for HER2
status than patients with the lowest mortality risk. The latter
was, however, not statistically significant. The association
between mortality risk and HER2 testing seemed to assume
an inverted U-shape (P for quadratic trend !0.001).5. Discussion
Using HER2 testing as an example, we have demon-
strated a significant association between perceived outcome
of patients as deemed by clinicians at the time of breast
cancer diagnosis and the choice to whether to test for
a new biomarkers status. There was a significant inverted
U-shaped association between the patient’s predicted mor-
tality risk and testing for HER2 status.
A limitation of our study is that only a small proportion
(6%) of patients were not tested for HER2 status. Despite
this small number, we were able to demonstrate that selec-
tion of patients for HER2 testing had not been random
during the study period.
Clinicians seem to voluntarily or involuntarily base their
choice whether to test for HER2 status, on the patient’s
estimated prognosis around time of diagnosis. In the
present study, a possible reason for not determining
biomarker status in women with poor prognosis, that is,
metastatic breast cancer in mid-2000s, could have been that
the information would not change the management of these
patients in our limited resource setting, as testing for HER2
Table 2. Association between 2-year predicted mortality risk* and HER2 testing in 888y Southeast Asian women with breast cancer
Quintile No. of patients Median 2-year mortality risk (%) OR of HER2 testing 95% CI for OR
1 178 1 1.00 d
2 181 2 1.48 0.55e3.98
3 174 4 2.53 0.78e8.22
4 179 8 1.46 0.54e3.93
5 176 24 0.36 0.17e0.77
Abbreviations: HER2, human epidermal growth factor receptor 2; OR, odds ratio; CI, confidence interval.
* Using Cox regression with age, ethnicity, tumor size, lymph node involvement, distant metastasis, tumor grade, estrogen receptor status, and
progesterone receptor status as predictors.
y Excluding 22 patients with missing tumor size.
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to afford treatment with trastuzumab or lapatinib or that
they were not included in clinical trials.
Many prognostic studieseinvestigating biomarkers have
been conducted using cancer registry data. Although the
testing techniques for the biomarkers were rightly empha-
sized, some of these studies had performed complete case
analysis with minimal attention paid to identify or address
possible selection bias [3,4]. Our finding clearly poses
limits to naive prognostic research in registries based on
complete case analysis. The prognostic value of a new
biomarker initially tested only in women with clinically
perceived outcome risks may deviate in any direction from
its true value. Possible solutions to address this would be to
assess whether missing information on biomarkers of inter-
est is random or nonrandom by comparing characteristics
or survival of patients who had information against those
with missing information [2], or restricting study to the part
of the cohort where biomarkers were routinely determined
[5]. Investigators may also use statistical methods, such as
imputation that have been found to yield more precise [10]
and valid [11,12] results compared with complete case
analysis.
In conclusion, selection of women for determination of
new biomarkers in regular clinical care for breast cancer
is not a random process but rather based on patients’
prognoses. Therefore, studies on the prognosis of (breast)
cancer focusing on gradually implemented new biomarkers,
using complete case analysis from existing cancer
registries, are to be interpreted with caution.Acknowledgments
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